Knockdown of DEGS1 significantly decreased the IC50 values of enzalutamide in both cell lines (Figures 8D, E), underscoring the role of DEGS1 in the acquisition of enzalutamide resistance in prostate cancer. This evidence concerns the gene DEGS1 and prostate carcinoma.